Abstract OT3-08-01: A phase 1 trial of LOXO-783, a potent, highly mutant-selective, brain-penetrant allosteric PI3Kα H1047R inhibitor in PIK3CA H1047R-mutant advanced breast cancer (aBC) and other solid tumors (PIKASSO-01, trial in progress)
Dejan Juric(Massachusetts General Hospital), Funda Meric‐Bernstam(The University of Texas MD Anderson Cancer Center), Matthew P. Hanley, Vincent Chau(Eli Lilly (United States)), Komal Jhaveri(Memorial Sloan Kettering Cancer Center), Lillian M. Smyth(Loxo Oncology at Lilly (United States)), Erika Hamilton(Sarah Cannon), Shiyao Liu(Southern Medical University), Muralidhar Beeram(Urology San Antonio)
Cited by 9
Related Papers
AACR Project GENIE: Powering Precision Medicine through an International Consortium
|Cancer Discovery|2017|2k
Role of the Ubiquitin-Proteasome Pathway in Regulating Abundance of the Cyclin-Dependent Kinase Inhibitor p27
|Science|1995|1.8k
Ubiquitination of hypoxia-inducible factor requires direct binding to the β-domain of the von Hippel–Lindau protein
|Nature Cell Biology|2000|1.6k
A Multiubiquitin Chain Is Confined to Specific Lysine in a Targeted Short-Lived Protein
|Science|1989|1.5k
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
|New England Journal of Medicine|2019|1.3k